OBSOLETE: Neuroepithelioma

Neuroepithelioma, also historically known as peripheral neuroepithelioma or peripheral primitive neuroectodermal tumor (pPNET), is an obsolete diagnostic term that was previously used to describe a group of small round cell tumors arising from neuroectodermal tissue outside the central nervous system. This entity has been reclassified and is now largely subsumed under the Ewing sarcoma family of tumors (ESFT), which share a common genetic hallmark — chromosomal translocations involving the EWSR1 gene, most commonly the t(11;22)(q24;q12) translocation producing the EWSR1-FLI1 fusion gene. The Orphanet entry for neuroepithelioma (ORPHA:2677) is marked as obsolete, reflecting this reclassification in modern oncologic and pathologic nomenclature. Historically, neuroepithelioma presented as a soft tissue or bone mass, most commonly in children, adolescents, and young adults. Tumors could arise in the chest wall, paravertebral region, extremities, or other soft tissue sites. Symptoms depended on tumor location and included pain, swelling, and compression of adjacent structures. The tumors were aggressive, with a propensity for local invasion and distant metastasis to lungs, bone, and bone marrow. Neuroepithelioma showed neural differentiation features on histology and immunohistochemistry, distinguishing it from classic Ewing sarcoma, though this distinction is no longer considered clinically meaningful. Treatment for tumors previously classified as neuroepithelioma follows current Ewing sarcoma protocols, which include multimodal therapy combining systemic chemotherapy (typically vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide), local control with surgery and/or radiation therapy, and in some cases high-dose chemotherapy with stem cell rescue for high-risk or relapsed disease. Prognosis depends on stage at diagnosis, tumor size, location, and response to initial chemotherapy. Patients seeking information about this condition should refer to current Ewing sarcoma resources for up-to-date management guidelines.

Common questions about OBSOLETE: Neuroepithelioma